| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.79 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,922,851 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,660,378 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
29 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
See Explanation of Responses |
– • • |
2023-06-26 |
4 |
D |
$9.10 |
$14,280,503 |
I/I |
(1,569,286) |
0 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– • • |
2023-06-26 |
4 |
D |
$9.10 |
$66,310,553 |
D/D |
(7,286,874) |
0 |
|
- |
|
| Perry Matthew D |
Director |
– • – |
2023-06-26 |
4 |
D |
$9.10 |
$392,565 |
D/D |
(43,139) |
0 |
|
- |
|
| Tuckson Reed Vaughn |
Director |
– • – |
2023-06-26 |
4 |
D |
$9.10 |
$442,615 |
D/D |
(48,639) |
0 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2023-06-26 |
4 |
D |
$9.10 |
$286,377 |
D/D |
(31,470) |
0 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2023-06-26 |
4 |
D |
$9.10 |
$159,678 |
D/D |
(17,547) |
0 |
|
- |
|
| Fong James K |
EVP & Chief Commercial Officer |
• – – |
2023-06-26 |
4 |
D |
$9.10 |
$32,442 |
D/D |
(3,565) |
0 |
|
- |
|
| Fong James K |
EVP & Chief Commercial Officer |
• – – |
2023-01-24 |
4 |
AS |
$6.00 |
$600,000 |
D/D |
(100,000) |
3,565 |
|
51% |
|
| Fong James K |
EVP & Chief Commercial Officer |
• – – |
2023-01-24 |
4 |
OE |
$0.95 |
$94,890 |
D/D |
100,000 |
103,565 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2023-01-24 |
4 |
AS |
$6.00 |
$511,923 |
D/D |
(85,317) |
29,440 |
|
51% |
|
| Craig Adam R |
President and CEO |
• • – |
2023-01-24 |
4 |
OE |
$0.84 |
$71,760 |
D/D |
85,317 |
31,557 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2023-01-03 |
4 |
AS |
$6.01 |
$509,224 |
D/D |
(84,683) |
29,440 |
|
53% |
|
| Craig Adam R |
President and CEO |
• • – |
2023-01-03 |
4 |
OE |
$0.84 |
$71,227 |
D/D |
84,683 |
114,123 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2023-01-03 |
4 |
AS |
$6.01 |
$162,423 |
D/D |
(27,021) |
17,127 |
|
53% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2023-01-03 |
4 |
OE |
$0.95 |
$25,640 |
D/D |
27,021 |
44,148 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-12-30 |
4 |
AS |
$6.00 |
$102,648 |
D/D |
(17,100) |
29,440 |
|
49% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-12-30 |
4 |
OE |
$0.84 |
$14,383 |
D/D |
17,100 |
33,840 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-12-30 |
4 |
A |
$5.11 |
$8,066 |
D/D |
1,579 |
29,440 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-12-30 |
4 |
AS |
$6.00 |
$83,096 |
D/D |
(13,847) |
17,127 |
|
49% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-12-30 |
4 |
OE |
$0.95 |
$13,139 |
D/D |
13,847 |
18,174 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-12-30 |
4 |
A |
$5.11 |
$1,093 |
D/D |
214 |
17,127 |
|
- |
|
| Craig Adam R |
President and CEO |
• • – |
2022-12-29 |
4 |
AS |
$6.00 |
$82,800 |
D/D |
(13,800) |
27,861 |
|
54% |
|
| Craig Adam R |
President and CEO |
• • – |
2022-12-29 |
4 |
OE |
$0.84 |
$11,607 |
D/D |
13,800 |
41,661 |
|
- |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-12-29 |
4 |
AS |
$6.00 |
$79,044 |
D/D |
(13,174) |
16,913 |
|
54% |
|
| Kirske David |
EVP, Chief Financial Officer |
• – – |
2022-12-29 |
4 |
OE |
$0.95 |
$12,501 |
D/D |
13,174 |
30,087 |
|
- |
|
229 Records found
|
|
Page 1 of 10 |
|
|
